Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 14/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305743 | 1.00 | CCR3 (0.62) | CCR3SIGMAR1CCR5OPRM1OPRK1 | |
| SCHEMBL6307230 | 0.90 | CCR3 (0.55) | CCR3CCR5 | |
| SCHEMBL6307232 | 0.90 | CCR3 (0.55) | CCR3CCR5 | |
| SCHEMBL6304036 | 0.86 | SIGMAR1 (0.58) | CCR3SIGMAR1OPRK1 | |
| SCHEMBL6304033 | 0.86 | SIGMAR1 (0.58) | CCR3SIGMAR1OPRK1 | |
| SCHEMBL6307072 | 0.86 | SIGMAR1 (0.53) | CCR3SIGMAR1 | |
| SCHEMBL6307066 | 0.86 | SIGMAR1 (0.53) | CCR3SIGMAR1 | |
| SCHEMBL6311003 | 0.85 | CCR3 (0.51) | CCR3CCR5 | |
| SCHEMBL6311005 | 0.85 | CCR3 (0.51) | CCR3CCR5 | |
| SCHEMBL6311625 | 0.84 | CCR3 (0.54) | CCR3CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | CCR3 2/4885SIGMAR1 140/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.